DermTech Announces New Scientific Advisory Board Members
The SAB provides important support and advice to DermTech, which advances its research and development of skin cancer and skin disease tests and treatment. The experience of each member of the SAB in dermatology, skin cancer, genomics or biotech innovations distinguishes them as industry leaders and experts in their respective fields.
Lisa Beck, M.D., is the co-director of the University of Rochester Medical Center for Allergic Disease Research and has served on the board of directors of the International Eczema Council since 2014. Specializing in the treatment of atopic dermatitis and eczema, Dr. Beck received her medical degree from the State University of New York at Stony Brook. Dr. Beck completed her dermatology residency at Duke University and an immunology research fellowship at Johns Hopkins University. Dr. Beck is currently serving as President-Elect of the Society of Investigative Dermatology (2020-2021).
George Han, M.D., Ph.D., currently serves as the System Medical Director for Dermatology and Chief of Teledermatology at the Mount Sinai Health System. Dr. Han is the current Vice President of the Dermatologic Society of Greater New York and a member of the Medical Board of the National Psoriasis Foundation. To date, Dr. Han has over 50 publications in well-respected journals such as the Journal of the American Academy of Dermatology, the Journal of Investigative Dermatology, the Journal of Infectious Diseases, the British Journal of Dermatology and the American Journal of Pathology. Dr. Han remains active in conducting both basic scientific research as well as clinical trials.
“Dr. Beck and Dr. Han bring extensive clinical and research experience in skin cancer and inflammatory skin diseases to our Scientific Advisory Board. We look forward to receiving their expertise as we leverage our innovative platform to pioneer new approaches in precision dermatology. The combined knowledge of our SAB across a wide range of dermatological specialties will continue to contribute to our success as we strive to use precision genomics to redefine the industry standard for the diagnosis and treatment of skin disease,” said John Dobak, M.D., CEO of DermTech.
For more information on the DermTech Scientific Advisory Board, please visit: https://dermtech.com/about-us/scientific-advisory-board/.
DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech’s mission is to transform dermatology with our non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech’s investor relations site at: http://www.dermtech.com./
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to: the performance, patient benefits, cost‑effectiveness, commercialization and adoption of DermTech’s products and the market opportunity therefor. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in (x) the “Risk Factors” section of the most recent Quarterly Report on Form 10Q filed by DermTech with the Securities and Exchange Commission (the “SEC”), and (y) other documents filed or to be filed by DermTech with the SEC. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
Source: DermTech, Inc.